✦ LIBER ✦

Phase II clinical and pharmacological study of oral 4-demethoxydaunorubicin in advanced non-pretreated small cell lung cancer

Book ID: 123337936
Publisher: Elsevier Science
Year: 1989
Tongue: English
Weight: 144 KB
Volume: 5
Category: Article
ISSN: 0169-5002
DOI: 10.1016/0169-5002(89)90471-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II clinical and pharmacological st

✍ Robert Milroy; Jeffrey Cummings; Stanley B. Kaye; Stephen W. Banham 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 298 KB

4-Demethoxydaunorubicin (4-DMDNR) is an oral anthracycline with antitumour activity demonstrated in a number of clinical studies. We have assessed the usefulness of 4-DMDNR in 16 patients with advanced small cell lung cancer, none of whom had received previous chemotherapy. There were no complete or

A phase II trial of oral 4′ demethoxydau

A phase II trial of oral 4′ demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer

✍ P. Presgrave; R. Woods; R. Kefford; D. Bell; D. Raghavan; J. Levi 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 216 KB

4' Demethoxydaunorubicin, an orally active daunorubicin analogue, was administered to 22 patients with inoperable non small cell lung cancer (NSCLC). Patients were stratified into good and poor risk categories and received doses of 45 mg/m 2 and 40 mg/m 2 respectively at 28 day intervals. All 22 pat

A Phase II Study of Single-Agent Oral Vi

A Phase II Study of Single-Agent Oral Vinorelbine in Patients with Pretreated Advanced Non–Small-Cell Lung Cancer

✍ David Rossi; Vincenzo Catalano; Paolo Alessandroni; Anna Fedeli; Stefano Luzi Fe 📂 Article 📅 2007 🏛 CIG Media Group, LP. 🌐 English ⚖ 127 KB

Clinical and pharmacological phase II st

Clinical and pharmacological phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer (NSCLC)

📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 167 KB

A phase II study of oral idarubicin (4-d

A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer

✍ Nicholas S. A. Stuart; Michael H. Cullen; Terrence J. Priestman; George R. P. Bl 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 352 KB

Idarubicin (4-demethoxydaunorubicin: DMDNR) is an orally active analogue of daunorubicin that has shown promising activity in animal and early clinical studies. We gave idarubicin in a phase II study to patients with advanced breast cancer unresponsive to hormonal manipulation and in some cases to s

A phase II study of oral weekly 4-demeth

A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer

✍ Smith, David B.; Howell, Anthony 📂 Article 📅 1987 🏛 Elsevier Science ⚖ 427 KB